

PT Jayamas Medica Industri Tbk (OMED IJ)

Company Update 1H 2025

July 2025

Table of Contents



0	Executive Summary
1	Company Overview
2	Business Overview
3	Key Investment Highlights
4	Growth Strategies
5	Financials & Operations

EXECUTIVE SUMMARY



EXECUTIVE SUMMARY





PT Jayamas Medica Industri Tbk (OMED or "The Company") founded in early 2000s. Since then, OMED has become a market leader in the Indonesian medical equipment and supplies market with a diverse product offering product portfolio consists of around 3,550 Active SKUs, supported by a wide-reaching distribution network, which spans across 514 cities and 34 provinces in Indonesia.

Product Category:



Supported with various number of brands:



We serve all customers across Indonesia:




1 National Distribution Center

23 Branch offices and warehouses

12 Sales offices

28 Omnichannel Stores

Backed with increasing awareness on healthcare:



Source: Company

COMPANY OVERVIEW



Management Profile



Board of Commissioners



Dr. Yacobus Jemmy Hartanto, MPH *President Commissioner*

Years of Experience: 44

Universitas
Udayana







Dr. Jemmy Hartanto is the founder of PT Jayamas Medica Industri Tbk. He started his career as a Doctor and he has been serving as the President Commissioner of OMED since 2004.



Siane Soetanto Commissioner Years of Experience: 38



Siane Soetanto serves as the Commissioner since 2021. She worked in the banking industry as the Head of Credit Reviewer in Bank Dagang Nasional Indonesia & Marketing division in UOB Bali.



David A. Worth *Independent Commissioner Years of Experience:* **41**



David A. Worth was appointed as the Independent Commissioner of OMED in 2024. He is also currently serving as Nominee Director at Phinma Education Manila as well as a non-executive board member at Sentosa Capital Singapore.

Board of Directors



Dra. Herlien Sri Ariani *President Director Years of Experience:* **36**



Airlangga University



Leonard Hartanto Operation Director Years of Experience: 14





Leonard Hartanto serves as the Operation Director since 2018 and is the eldest son of Dr. Jemmy Hartanto. He started working in OMED as the Purchasing Manager from 2013 to 2017.



Louis Hartanto Marketing Director Years of Experience: 12





Louis Hartanto was appointed as the Marketing Director in 2021 and is the youngest son of Dr. Jemmy Hartanto. He initially started his career as the Director of PT Intisumber Hasil Sempurna since 2013.



Eka Suwignyoo Finance Director Years of Experience: 24




Petra Christian University

Eka Suwignyoo was first appointed as the Finance Director in 2022. Prior to joining, he has worked in several companies and held strategic position such as Finance Analyst in PT HM Sampoerna.

Dra. Herlien Sri Ariani was appointed as the President Director of OMED in 2018. She started joining OMED as the Head of Production since 2001.

Shareholders Structure





Source: Company (1) As of June 30, 2025

⁽²⁾ As of May 20, 2025 the company is conducting shares buyback in response to fluctuating marketing conditions.

Key Milestones



Our Key Accomplishment Since 1992

2000 1992 2002 2006 2016 2022 2023 2024 - Present

VENTURED

Distribution **Business**



KRIAN

Total Area 2,200 sqm



GROUND BREAKING

New Facility Batang, Central Java

JOINT VENTURES

with Foreign Entities



KRIAN EXPANSION

8,000 sqm





MOJOAGUNG

Total Area 23,707 sqm

IPO IDR 828 Billion

Mojoagung Facility

EXPANDING

EXPANDING

Export to USA and other countries

ESTABLISHED the Brand in 2000

Source: Company

BUSINESS OVERVIEW




Product Portfolio



crutches and hernia pants

Sales by Products – 1H 2025




Includes commode chairs, wheelchairs, and electric and non-electric patient beds

Product Portfolio



Sales by Products – 1H 2025 (Top 5 in Medical Disposable & Consumables)



Production Facility



KRIAN FACILITY



MOJOAGUNG FACILITY



BATANG FACILITY



	Krian	Mojoagung	Batang
Year of Commencing	2002	2016	2024
Manufacturing Facilities	21,000 Sqm	67,846 Sqm	35,650 Sqm
Location	Ea	ast Java	Central Java
ISO	ISO 13485 Quality Quality Management Systems Systems Systems	ISO 13485 Quality Management Systems ISO 9001 Quality Management Systems	-
Production Focus	Syringes, Needles, Patient Monitor	Mask, Infus Set, IV, Underpad, Dialysis Fluid, Antiseptic & Disinfectant, Foley Catheter, Pregnancy Test, Wound Care, BCTs	Gauze

Source: Company 1

Prominent Customer Profile



Our Major Global Customer & Revenue Contribution Each Segment

1H 2025



















RSUD Dr. SOETOMO











EXPORT











Dr. MOEWARDI









Revenue Channels



Sales by Channel



- Distributor with e-Catalogue permits are able to on-sell to government, while distributor without permits may only supply our products to private institutions
- Supplies all products either directly via IHSG branches or indirectly via distributors in locations not covered by IHSG




- Supplies all product for hospitals
- Supply of primarily blood collection tubes and medical supplies to private clinics, laboratories, and dentists
- Supplies all products either directly via IHSG branches or indirectly via distributors in locations not covered by IHSG




- Includes drugstores, SME businesses and other small retailers
- Supplies medical disposable, wound care, antiseptic, and disinfectant products, among others




Supplies medical equipment and disposables to government bodies and entities such as Puskesmas









Sales by Brands



KEY INVESTMENT HIGHLIGHT



Competitive Advantages



ONE STOP SHOPPING

7 Product Categories

Approximately 3,550 Active SKUs



DIVERSE SALES CHANNELS







Medical Facilities





EXTENSIVE DISTRIBUTION

1 National Distribution Center

12 Sales Offices

23 Branch Offices & Warehouses

28 Stores



MANUFACTURING DIVISION

>40% Locally Manufactured Products (TKDN)

KRIAN



Focus in Syringes Production

MOJOAGUNG



 Requires in Heavy Workers Production

BATANG



 Focused in Fabrication Material (Gauze)

Main Competitors' Brand



TOP- SELLING PRODUCTS	One Med	Company B	Company C	Company D	Company E	Company F	Company G	Company H	Company I	Company J
Face Mask		√								
Pregnancy Test	bteONG S		✓							
Gauze & Woundcare	Pecking of the second of the s			✓	✓					
Piston Syringe	Sea from made 146 1 1/2 Restrict on the 16 1 1					√	√			
Antiseptic								✓		
Disinfectant	Augit, Gd								✓	\checkmark

GROWTH STRATEGIES



Capacity and Market Expansion



KRIAN BATANG MOJOAGUNG















Business Expansion Plan	Estimated Budget (IDR Billion)	Use of Proceed (IDR Billion)*	Details
Construction of Buildings, Procurement of Production Machinery and Equipment	IDR 425	IDR 301	New buildings in Batang, new office building in Mojoagung, new machinery in Batang and Krian
National Distribution Centre, Warehouse, and Retail Stores	IDR 100	IDR 61	Expansion of stores in Banjarmasin, Depok, Pontianak, and Bali
Development on Digital Marketing and Sales	IDR 32	IDR 16	Bali branches

Completion of the Mojoagung Plant Increases OneMed's Production Capacity by 12% of Total Capacity

Global Partnership (Export)



Riding Southeast Asia's Export Momentum to the U.S.

Level Playing Field = New Opportunity

- As of August 2025, the U.S. now applies a uniform 19% tariff to major Southeast Asian exporters: Indonesia, Thailand, Malaysia, Cambodia, Philippines.
- Creates a fairer, more predictable trade environment.
- Focus shifts from tariff gaps to execution, reliability, and cost-efficiency.

OMED is well-positioned to scale in this open, competitive landscape.

Why OMED Stands Out

- One of Indonesia's largest medical disposables manufacturers
- Low-cost structure with local production and regional supply chains
- 2025–2026 roadmap: validation, mold development, machinery acquisition, export launch
- Compliance-ready and open to U.S.-focused partnerships


OMED delivers what U.S. buyers value most: costefficiency, reliability, and scale readiness.

Strategic Tailwinds

- U.S. buyers are diversifying away from China, turning attention to Southeast Asia
- Indonesia offers a stable environment and resilient supply chains
- OMED is well-positioned to capture upcoming export opportunities in medical consumables.

Export marks a key step for OMED, with significant growth potential in the years ahead.

Tariff Comparison (Exports to U.S.)



Source: Reuters, CNA


FINANCIAL & OPERATIONS




Financial Overview




Revenue (In Billion Rupiah)




Assets (In Billion Rupiah)




EBITDA (In Billion Rupiah)




Liabilities (In Billion Rupiah)



Net Profit (In Billion Rupiah)



Equity (In Billion Rupiah)



Source: Company's Financial Statement

Operational Highlight



Production (in thousand units)	1H24	1H25	YoY	Price (in IDR)	1H24	1H25	YoY	Sales (in IDR)	1H24	1H25	YoY
Sales Volume				Average Selling Price				Total Sales			
Disposable & Consumables	754,618	805,795	6.78%	Disposable & Consumables	593	567	-4.45%	Disposable & Consumables	447,488,634	456,589,250	2.03%
Wound Care	168,570	188,676	11.93%	Wound Care	812	803	-1.05%	Wound Care	136,878,815	151,599,138	10.75%
Antiseptic & Dialysis Fluid	208,877	216,343	3.57%	Antiseptic & Dialysis Fluid	473	473	-0.05%	Antiseptic & Dialysis Fluid	98,798,661	102,277,088	3.52%
Diagnostic & Equipment	1,209	2,236	84.87%	Diagnostic & Equipment	82,025	47,274	-42.37%	Diagnostic & Equipment	99,194,426	105,688,258	6.55%
Walking Aids & Rehab	758	843	11.26%	Walking Aids & Rehab	51,344	54,614	6.37%	Walking Aids & Rehab	38,900,718	46,037,442	18.35%
Biotech & Lab	64,534	80,012	23.98%	Biotech & Lab	592	532	-10.06%	Biotech & Lab	38,204,187	42,601,797	11.51%
Hospital Furniture	36	29	-19.18%	Hospital Furniture	554,102	715,183	29.07%	Hospital Furniture	20,182,620	21,053,160	4.31%
Total	1,198,602	1,293,934	7.95%					Total	879,648,061	925,846,133	5.25%

Source: Company's Internal Data

Key Performance Ratios



Key Ratios	2021	2022	2023	2024	1H 2024	1H 2025			
Profitability Ratios									
Revenue Growth	11.6%	-21.9%	-0.1%	8.6%	8.4%	5.3%			
Gross Profit Margin	40.6%	35.1%	31.8%	33.1%	33.2%	33.8%			
EBITDA Margin	34.7%	25.0%	23.1%	21.6%	21.4%	21.1%			
Net Profit Margin	25.6%	16.8%	14.9%	17.2%	16.5%	16.7%			
Return on Asset	33.0%	11.6%	10.0%	11.5%	5.3%	5.4%			
Return on Equity	45.8%	14.0%	11.5%	13.0%	6.3%	6.0%			
	Liqu	idity and Solve	ency Ratios						
Current Ratio	5.5	9.6	15.2	7.7	6.1	8.6			
Int. Bearing Debt to Equity Ratio	0.15	0.10	0.08	0.06	0.08	0.02			
Debt to Equity Ratio	0.39	0.21	0.15	0.13	0.18	0.11			
Efficiency Ratios									
Receivable Days	29	39	43	51	55	54			
Inventory Days	112	161	186	174	192	183			
Payable Days	48	58	29	24	27	28			
Cash Conversion Cycle	93	141	200	201	220	209			

Source: Company's Financial Statement

Corporate Highlights & Public Engagements









Corporate Highlights & Public Engagements











THANK YOU

PT Jayamas Medica Industri Tbk (OMED IJ)



CONTACT US







https://www.tokopedia.com/onemed



https://shopee.co.id/onemed



https://omed.idx